ClinicalTrials.gg
TerminatedNCT00184548CONTROLUpdated Jun 25, 2014Results posted

Evaluation of Recombinant Factor VIIa in Patients With Severe Bleeding

A Phase 3 interventional study of eptacog alfa (activated) and placebo in Acquired Bleeding Disorder and Trauma, sponsored by Novo Nordisk A/S. Terminated at 14 sites in 14 countries. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2014-06-25.

Sponsored by Novo Nordisk A/S · Phase 3, Interventional, and Treatment

Why this study was terminated
See termination reason in detailed description

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
554
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Study summary

This trial is conducted globally. The purpose of the trial is to evaluate that activated recombinant human factor VII (eptacog alfa (activated)) is safe and effective in severely injured trauma patients by assessing mortality and morbidity.

Please note that this trial and trial F7TRAUMA-1648 (NCT00323570) have been merged.

Read the detailed description

The decision to discontinue the F7TRAUMA-1711 trial is not due to any safety concerns. The result of the pre-planned futility analysis performed in June 2008 predicted a very low likelihood of reaching a successful outcome on the primary efficacy endpoint at the end of the trial and as a consequence, the company has decided to close the trial as this juncture.

02

Conditions studied

  • Acquired Bleeding Disorder
  • Trauma

Browse trials for

03

In context

Wounds and Injuries

2,218 studies on the registry are indexed under Wounds and Injuries; 441 are open to participants now.

This study's enrollment of 554 is above the median of 70 across 1,424 interventional studies indexed under Wounds and Injuries.

Browse Wounds and Injuries studies →

Lead sponsor

Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.

Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  • Trauma injury (blunt and/or penetrating) with evidence of active hemorrhage (torso and/or proximal lower extremity) to blood component therapy and surgical haemostatic procedures at the time of randomisation
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
554 participants (actual)

Study arms

  • Experimental
    rFVIIa, Blunt Trauma

    Drug: eptacog alfa (activated)

  • Placebo comparator
    Placebo, Blunt Trauma

    Drug: placebo

  • Experimental
    rVIIa, Penetrating Trauma

    Drug: eptacog alfa (activated)

  • Placebo comparator
    Placebo, Penetrating Trauma

    Drug: placebo

Interventions

  • Sterile, freeze-dried powder in single-use vials to be reconstituted with sterile water for injection. Three doses of 200, 100 and 100 mcg/kg to be administered bolus i.v. (intravenous) over approx. three hours.

  • Drugplacebo

    placebo

06

What researchers measure

Primary outcomes

  1. Mortality

    Number of participants to die from day 0 to day 30 from all causes.

    Time frame: from day 0 to 30

  2. Morbidity

    Morbidity reflects the number of patients who had pulmonary and/or renal dysfunction requiring ongoing medical intervention on day 30.

    Time frame: from day 0 to day 30

Secondary outcomes

  1. Number of Days Alive and Free of Pulmonary and/or Renal Dysfunction Requiring Medical Intervention

    The number of days alive and free of pulmonary and/or renal dysfunction requiring medical intervention from day 0 to day 30.

    Time frame: from day 0 to day 30

  2. Time to Death From Time of First Dose

    The time of first dose refers to the time of the first dose of rFVIIa or placebo.

    Time frame: from day 0 to day 30

  3. Number of Units of Transfused Red Blood Cells From Time of First Dose

    The number of units of transfused red blood cells in the first 24 hours from the time of the first dose of rFVIIa or placebo.

    Time frame: from hour 0 to 24

  4. Number of Patients Receiving 10 Units or More (Massive Transfusion) of Red Blood Cells From Time of Injury

    The number of patients receiving 10 units or more of red blood cells in the first 24 hours from the time of injury.

    Time frame: from hour 0 to 24

  5. Number of Units of All Allogeneic Transfusions From Time of First Dose

    The number of units of all allogeneic transfusions in the first 24 hours from the time of the first dose of rFVIIa or placebo.

    Time frame: from hour 0 to 24

07

Results

Posted Nov 26, 2009
Limitations and caveats
Trial was terminated after planned interim analysis for futility showed a lower than expected conditional power for showing superiority (11.2% \[actual\] vs. 50% \[required\]). 554 of 1502 planned patients were included in the intent-to-treat population.

Participant flow

150 trial sites globally.

Participant flow — Overall Study
MilestonerFVIIa, Blunt TraumaPlacebo, Blunt TraumarVIIa, Penetrating TraumaPlacebo, Penetrating Trauma
Started2262554745
Exposed2242504640
Completed2182424438
Not completed81337

Outcome measures

PrimaryMortality

Number of participants to die from day 0 to day 30 from all causes.

Time frame:
from day 0 to 30
Reported as:
Number · Participants
Mortality
ParticipantsrFVIIa, Blunt TraumaPlacebo, Blunt TraumarFVIIa, Penetrating TraumaPlacebo, Penetrating Trauma
Mortality2426——
Statistical analysis
  • rFVIIa, Blunt Trauma vs Placebo, Blunt Trauma · Regression, Logistic · p = 0.934 (Two-sided significance level 5%)
  • rFVIIa, Blunt Trauma vs Placebo, Blunt Trauma · Cox Proportional Hazards Model · p = 0.589 (Two-sided significance level 5%) · Hazard ratio (hr): 1.18 · 95% CI 0.64 to 2.17
PrimaryMorbidity

Morbidity reflects the number of patients who had pulmonary and/or renal dysfunction requiring ongoing medical intervention on day 30.

Time frame:
from day 0 to day 30

No measurements were reported for this outcome.

SecondaryNumber of Days Alive and Free of Pulmonary and/or Renal Dysfunction Requiring Medical Intervention

The number of days alive and free of pulmonary and/or renal dysfunction requiring medical intervention from day 0 to day 30.

Time frame:
from day 0 to day 30
Reported as:
Mean · Days
Number of Days Alive and Free of Pulmonary and/or Renal Dysfunction Requiring Medical Intervention
DaysrFVIIa, Blunt TraumaPlacebo, Blunt TraumarFVIIa, Penetrating TraumaPlacebo, Penetrating Trauma
Number of Days Alive and Free of Pulmonary and/or Renal Dysfunction Requiring Medical Intervention17.2 ± 10.316.4 ± 10.3——
Statistical analysis
  • rFVIIa, Blunt Trauma vs Placebo, Blunt Trauma · ANCOVA · p = 0.308 · Ls means: 0.90 · 95% CI -0.83 to 2.63
SecondaryTime to Death From Time of First Dose

The time of first dose refers to the time of the first dose of rFVIIa or placebo.

Time frame:
from day 0 to day 30

No measurements were reported for this outcome.

SecondaryNumber of Units of Transfused Red Blood Cells From Time of First Dose

The number of units of transfused red blood cells in the first 24 hours from the time of the first dose of rFVIIa or placebo.

Time frame:
from hour 0 to 24
Reported as:
Mean · Units of transfused red blood cells
Number of Units of Transfused Red Blood Cells From Time of First Dose
Units of transfused red blood cellsrFVIIa, Blunt TraumaPlacebo, Blunt TraumarFVIIa, Penetrating TraumaPlacebo, Penetrating Trauma
Number of Units of Transfused Red Blood Cells From Time of First Dose6.9 ± 10.48.1 ± 10.9——
Statistical analysis
  • rFVIIa, Blunt Trauma vs Placebo, Blunt Trauma · Wilcoxon (Mann-Whitney) · p = 0.038 · Hodges-lehmann shift estimate: 1.0 · 95% CI 0 to 2
SecondaryNumber of Patients Receiving 10 Units or More (Massive Transfusion) of Red Blood Cells From Time of Injury

The number of patients receiving 10 units or more of red blood cells in the first 24 hours from the time of injury.

Time frame:
from hour 0 to 24
Reported as:
Number · Participants
Number of Patients Receiving 10 Units or More (Massive Transfusion) of Red Blood Cells From Time of Injury
ParticipantsrFVIIa, Blunt TraumaPlacebo, Blunt TraumarFVIIa, Penetrating TraumaPlacebo, Penetrating Trauma
Number of Patients Receiving 10 Units or More (Massive Transfusion) of Red Blood Cells From Time of Injury111134——
Statistical analysis
  • rFVIIa, Blunt Trauma vs Placebo, Blunt Trauma · Regression, Logistic · p = 0.384 · Odds ratio (or): 1.175 · 95% CI 0.817 to 1.690
SecondaryNumber of Units of All Allogeneic Transfusions From Time of First Dose

The number of units of all allogeneic transfusions in the first 24 hours from the time of the first dose of rFVIIa or placebo.

Time frame:
from hour 0 to 24
Reported as:
Mean · Units of allogeneic transfusions
Number of Units of All Allogeneic Transfusions From Time of First Dose
Units of allogeneic transfusionsrFVIIa, Blunt TraumaPlacebo, Blunt TraumarFVIIa, Penetrating TraumaPlacebo, Penetrating Trauma
Number of Units of All Allogeneic Transfusions From Time of First Dose17.1 ± 26.820.7 ± 25.7——
Statistical analysis
  • rFVIIa, Blunt Trauma vs Placebo, Blunt Trauma · Wilcoxon (Mann-Whitney) · p = 0.030 · Hodges-lehmann shift estimate: 2 · 95% CI 0 to 4

Adverse events

Collected over Adverse events were collected in a timespan of 90 days.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
rFVIIa, Blunt Trauma—147/224 (65.6%)108/224 (48.2%)
Placebo, Blunt Trauma—177/250 (70.8%)125/250 (50%)
rVIIa, Penetrating Trauma—18/46 (39.1%)26/46 (56.5%)
Placebo, Penetrating Trauma—20/40 (50%)24/40 (60%)
Most frequent serious events
Showing 10 of 267
Most frequent serious events
EventrFVIIa, Blunt TraumaPlacebo, Blunt TraumarVIIa, Penetrating TraumaPlacebo, Penetrating Trauma
SepsisInfections and infestations24/22430/2503/462/40
PneumoniaInfections and infestations11/22426/2503/462/40
Acute respiratory distress syndromeRespiratory, thoracic and mediastinal disorders8/22418/2500/463/40
Multi-organ failureGeneral disorders10/22417/2501/461/40
Deep vein thrombosisVascular disorders14/22414/2500/462/40
Small intestinal obstructionGastrointestinal disorders0/2240/2500/462/40
PneumothoraxRespiratory, thoracic and mediastinal disorders6/2241/2502/462/40
Septic shockInfections and infestations5/22412/2500/460/40
Cardiac arrestCardiac disorders7/2248/2502/461/40
Renal failureRenal and urinary disorders3/2243/2502/460/40
Most frequent other events
Showing 10 of 22
Most frequent other events
EventrFVIIa, Blunt TraumaPlacebo, Blunt TraumarVIIa, Penetrating TraumaPlacebo, Penetrating Trauma
PyrexiaGeneral disorders27/22427/25011/4614/40
TachycardiaCardiac disorders12/22413/2506/462/40
HypokalaemiaMetabolism and nutrition disorders28/22432/2505/463/40
HypomagnesaemiaMetabolism and nutrition disorders21/22428/2505/465/40
HypocalcaemiaMetabolism and nutrition disorders25/22430/2504/463/40
HypertensionVascular disorders0/2240/2505/463/40
HypotensionVascular disorders24/22425/2504/464/40
HyperkalaemiaMetabolism and nutrition disorders0/2240/2501/464/40
HypophosphataemiaMetabolism and nutrition disorders6/22414/2504/462/40
HypothermiaGeneral disorders15/22421/2500/460/40

Baseline characteristics

Age, Continuous
Age, Continuous(years)rFVIIa, Blunt TraumaPlacebo, Blunt TraumarFVIIa, Penetrating TraumaPlacebo, Penetrating TraumaTotal
Mean39.2 ± 14.439.9 ± 14.233.8 ± 11.929.4 ± 10.338.4 ± 14.1
Sex: Female, Male
Sex: Female, Male(Participants)rFVIIa, Blunt TraumaPlacebo, Blunt TraumarFVIIa, Penetrating TraumaPlacebo, Penetrating TraumaTotal
Female596533130
Male1621824337424
08

Study locations

14 sites
  • Novo Nordisk Clinical Trial Call Center
    Princeton, New Jersey 08540, United States
  • Säo Paulo, 05001-400, Brazil
  • Prague, 16000, Czech Republic
  • Paris La défense cedex, 92932, France
  • Mainz, 55127, Germany
  • Vouliagment, 16671, Greece
  • Kowloon, Hong Kong
  • Budapest, 1025, Hungary
  • Rome, 00144, Italy
  • Alphen a/d Rijn, Netherlands
  • Sandton, 2146, South Africa
  • Madrid, 28033, Spain
  • Zurich, CH-8050, Switzerland
  • Crawley, RH11 9RT, United Kingdom
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2005, a primary completion of Sep 2008 and a completion of Sep 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Nov 2009, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 9, 2005
First posted
Sep 16, 2005
Start
Oct 2005
Primary completionActual
Sep 2008
CompletionActual
Sep 2008
Results first posted
Nov 26, 2009
Last update
Jun 25, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 25, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00184548
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Sep 16, 2005
Start date
Oct 2005
Primary completion
Sep 2008
Completion
Sep 2008
Results posted
Nov 26, 2009
Last update
Jun 25, 2014

Study contacts

Global Clinical Registry (GCR, 1452)
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jun 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Recombinant FVIIa

Start the discussion